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We report an unusual case of a 78-year-old Caucasian female, who presented with peritoneal carcinomatosis and hypercalcemia,
and was found to have a rapidly progressive primary squamous cell carcinoma of the urinary bladder. Squamous cell bladder
carcinoma is a rare malignancy in the United States, accounting for just 1–3% of bladder tumors. Interestingly our patient lacked
theestablishedriskfactors,includingexposuretotheparasiteSchistosomahaematobium,recurrenturinarytractinfections,bladder
calculi, radiation exposure, chronic indwelling catheter, neurogenic bladder, or tobacco abuse. Although hypercalcemia has been
rarely described, an initial presentation of peritioneal carcinomatosis has not been previously reported.
1.CaseReport
A 78-year-old Caucasian woman presented with a subacute
onset of diﬀuse abdominal pain, associated with progressive
abdominal distention, nausea, and anorexia. Her initial labs
werenotableforhyponatremia(Sodiumlevelof127mEq/L),
and hypercalcemia (corrected calcium level of 14mg/dL),
and acute prerenal failure (Blood Urea Nitrogen 55mg/dL,
creatinine 4.8mg/dL), which were new compared to two
weeks prior. Her hemoglobin, liver enzymes, coagulation
panel, and lactate dehydrogenase (LDH) were within nor-
mal limits. Urinalysis revealed pyuria, microscopic hema-
turia, mild proteinuria, and culture grew Escherichia coli.
She was treated with intravenous ﬂuids, zoledronic acid,
and antibiotics, and her renal function and electrolytes
improved. A Computed Tomography (CT) scan of the
chest/abdomen/pelvis with oral contrast (Figure 1) revealed
a thickened peritoneum and omentum (arrowheads) and
ascites (arrows), consistent with peritoneal carcinomatosis.
Visualization of her pelvis was limited due to streak artifact
from bilateral hip prostheses. She had no evidence of
obstruction, mass lesions, or lymphadenopathy, and her
visualized organs were normal in appearance.
Her past medical history was remarkable for hyperten-
sion, diabetes mellitus, osteoarthritis, and coronary artery
disease. She denied any use, past or present, of alcohol,
tobacco, or illicit drugs. She was of Jewish descent and lived
in the US her entire life as a homemaker, with no history
of foreign travel. She lived alone and was very functional
at baseline. Menses began at age thirteen, and menopause
at age ﬁfty. She had two children who were alive and well.
She was up to date with her health maintenance and cancer
screening, and she had no history of abnormal pap smear,
mammogram, or colonoscopy. She had no family history of
malignancy.
S e r u mt u m o rm a r k e r sC E Aa n dC A1 9 - 9w e r en o r m a l ,
CA-125 was mildly elevated at 94U/mL (normal range: 0–
37U/mL). Endovaginal ultrasound was performed showing
normal appearing ovaries. Diagnostic paracentesis was per-
formed, which showed a serum-ascites albumin gradient
(SAAG) < 1.1, with negative culture. Abdominal ﬂuid
cytology showed squamoid-appearing cells suspicious for,
but nondiagnostic of, malignancy.
Malignancy remained the most likely diagnosis, and
a tissue diagnosis was indicated for further management;
however, prior to undergoing an open biopsy and possi-
ble debulking, she suﬀered a non-ST-elevation myocardial
infarction (MI). During recovery from the MI, she was noted
to have feculent material in her urinary catheter bag. A CT
scanconﬁrmedthepresenceofanenterovesicularﬁstula.She2 Advances in Urology
Figure 1
underwent urgent exploratory laporotomy, which revealed a
large dense tumor mass involving the midline periumbiical
area contiguous with the bladder, intraperitoneal enteric
contents, and a perforation was identiﬁed in the dome of
the bladder. The bladder dome was excised and closed in
the three layers. Bladder tumor and peritoneal biopsies were
obtained for pathologic assessment.
The peritoneal biopsy showed invasive squamous cell
carcinoma, keratinizing type. The bladder also showed inva-
sive keratinizing squamous cell carcinoma involving the full
thickness of the wall and extending into the perivesical soft
tissue. The adjacent bladder mucosa showed focal squamous
cell carcinoma in situ and extensive squamous metaplasia
of the surrounding benign urothelium (Figure 2). Panel
(a) shows an area of invasive, keratinizing squamous cell
carcinoma that has inﬁltrated beyond the muscularis propria
(detrusor muscle) and into the perivesical adipose tissue.
There is an associated desmoplastic reaction to the tumor.
Panel (b) demonstrates the extensive squamous metaplasia
seen in the background benign urothelium. Adjacent to the
invasive tumor were foci of squamous cell carcinoma in situ
(Panel (c)). The combination of these ﬁndings supported the
ﬁnal diagnosis of primary squamous cell carcinoma of the
urinary bladder.
Shortly after the ﬁstula repair, she began to clinically
decline with a deterioration of her mental status, worsening
pain, and concern for progressive disease. The decision was
made by her family not to pursue aggressive treatment. She
died on hospital Day 23 and autopsy was declined.
2. Discussion
Peritoneal carcinomatosis is a common presentation of
selected advanced stage tumors, or as a later complication of
disease progression or recurrence in numerous tumor types.
(a)
(b)
(c)
Figure 2: Panel (a) shows an area of invasive, keratinizing
squamous cell carcinoma that has inﬁltrated beyond the muscularis
propria (detrusor muscle) and into the perivesical adipose tissue.
There is an associated desmoplastic reaction to the tumor. Panel
(b) demonstrates the extensive squamous metaplasia seen in the
background benign urothelium. Adjacent to the invasive tumor
were foci of squamous cell carcinoma in situ (Panel (c)). Original
magniﬁcation—200× (panel (a)), 400× (panels (b), and (c)).
In adult females, the most common etiology is ovarian ade-
nocarcinoma, although carcinomas of the gastrointestinal
tract, lung, or breast, or primary peritoneal carcinoma can
produce this clinical syndrome. Other rarer tumor types that
should be considered are cervical, endometrial, peritoneal
mesothelioma, or lymphoma. In addition to looking for the
primary tumor site, ascitic ﬂuid cytology may be useful inAdvances in Urology 3
making the diagnosis. However, the sensitivity of cytology
ranges from 58–75% [1], depending on the number of
specimens processed, the quality of the specimens, and the
tumor type. Serum tumor marker elevation is common, but
is nonspeciﬁc and can be misleading [2]. Omental biopsy
is often performed in patients to verify malignancy when
a primary site cannot be established. Women with normal
appearing ovaries, if no other apparent primary site is found,
are usually considered to have primary peritoneal carcinoma
[3].
Squamous cell carcinoma (SCC) of the bladder is a
rare malignancy in the United States, accounting for 1–
3% of bladder tumors [4]. It is most common in the 7th
decade of life, and males and African Americans are most
likely to be aﬀected. Infection with the parasite Schistosoma
haematobiumisanimportantriskfactorinpartsoftheworld
where the organism is endemic. However, in the United
Statesnearlyallcasesarenonschistomalinorigin.Bothschis-
tosomal and nonschistosomal cases of SCC of the bladder
typically show a background of squamous metaplasia, and
in many cases SCC in situ may be present, which provides
indirect evidence that the invasive SCC is in fact a primary
bladder squamous carcinoma [5]. In the United States, risk
factors for SCC of the bladder include those situations
that commonly induce keratinizing squamous metaplasia, a
process that results from repeated urothelial injury. Thus,
recurrent urinary tract infections, bladder calculi, radiation
exposure, chronic indwelling catheters, neurogenic bladder,
and cigarette smoking are all risk factors. Interestingly, our
patientlackedexposuretoalloftheseestablishedriskfactors.
Nearly all patients with SCC of the bladder present
with hematuria. Our patient did not have gross hematuria,
and microscopic hematuria was initially attributed to her
underlying urinary tract infection. Less common presenting
symptoms can include irritative bladder symptoms, weight
loss, and urinary obstruction. The majority of bladder SCCs
are high grade, high stage tumors with most cancers having
muscle invasion at the time of diagnosis. If on biopsy a
diagnosisofsquamouscellcarcinomainsituismadewithout
an invasive component identiﬁed, the clinician should
consider rebiopsy or close clinical follow up, as most patients
with SCC in situ either concurrently have muscle-invasive
SCC or will develop muscle-invasive disease within months
of the diagnosis of in situ SCC. Of note, in order to label a
bladder tumor as a pure squamous cell carcinoma, thorough
pathologic sampling should be performed to exclude the
presence of an invasive high grade urothelial carcinoma
component. If the latter is, in fact, documented, the tumor
should not be referred to as a squamous cell carcinoma but
rather termed (and treated as) invasive high grade urothelial
carcinoma with squamous diﬀerentiation. The ﬁnding of
squamous metaplasia, as well as SCC in situ,a si no u r
case, is also helpful in determining that a tumor is a true
primary squamous cell carcinoma of the bladder as opposed
to urothelial carcinoma with squamous diﬀerentiation or
metastasis from another site.
There are limited data available regarding how to treat
patients with advanced SCC of the bladder as they tend to be
excluded from clinical trials studying urothelial carcinoma.
Treatment of clinically localized disease is usually surgical
since these tumors may be resistant to chemotherapy and
radiation, similar to squamous cell carcinomas of other sites
[6]. Chemotherapeutic regimens for urothelial carcinoma
are sometimes used but with variable results [7, 8], though
chemotherapy for nonbilharzial SCC is under-studied. Prog-
nosis for patients with SCC of the bladder is poor, and
most die from their disease within 1–3 years of diagnosis.
The reported 5-year survival rate is 33–48% [9]. Death is
usually due to locoregional progression (oftentimes ureteral
or bladder neck obstruction and subsequent renal failure),
and distant metastases are rare.
Primary squamous cell carcinoma of the bladder pre-
senting as peritoneal carcinomatosis has not been reported
in the literature. In patients who present with a clinical
picture of peritoneal carcinomatosis, primary bladder SCC,
as well as carcinomas of the urinary tract in general, could
be considered in the diﬀerential diagnosis, particularly when
aggressive and potentially morbid procedures are being
considered (e.g., surgical debulking for presumed primary
peritoneal carcinomatosis).
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